Jyong Biotech Ltd (MENS)
Jyong Biotech Ltd. is a biotechnology company focused on developing and commercializing plant-derived therapies for urinary system diseases. Its pipeline includes MCS-2 for benign prostatic hyperplasia and lower urinary tract symptoms, PCP for prostate cancer, and a program for interstitial cystitis and bladder pain syndrome. The company targets markets in the United States, the European Union, and Asia. Founded in 2002, Jyong Biotech is headquartered in New Taipei City, Taiwan. Its common stock trades on the NASDAQ under the symbol MENS.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MENS
|
$1.87
|
-11.7% Downside
|
Fair
|
Not available
|
Not available
|
Weak
|
0.0%
|
152.9 M
|
174.7 M
|
10.4%
|
36.3%
|
-10.2
|
65.1%
|
